Evidence map›Paper›PMID 35111011›Full record

ArticleCase reports in oncology

So-Called Serous Carcinoma of the Uterine Cervix with

Ruth Gabriela Herrera Gómez, Delfyne Hastir, Aikaterini Liapi, Ana Dolcan, Fernanda G Herrera, Patrice Mathevet, Apostolos Sarivalasis

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ruth Gabriela Herrera GómezOncology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Delfyne HastirPathology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Aikaterini LiapiOncology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Ana DolcanOncology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Fernanda G HerreraRadiation Oncology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Patrice MathevetDepartment of Obstetrics and Gynecology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Apostolos SarivalasisOncology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
University of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serous carcinoma of the uterine cervix (SCUC) is now believed to be a morphological variant of an HPV-associated endocervical adenocarcinoma or a metastasis from a serous carcinoma of the upper tract. In terms of mutational status as detected by next-generation sequencing (NGS), this controversial entity has not been characterized yet. We describe the case of a patient with a carcinoma categorized as stage IVB SCUC, initially treated with carboplatin, paclitaxel, and bevacizumab, followed by maintenance with bevacizumab. After locoregional progression, radiotherapy was administered. Unfortunately, further progression was observed, and carboplatin was resumed. Considering the presence of a

Indexed as

BRCA mutationCervix serous carcinomaRare tumors

Identifiers

PMID35111011
PMCPMC8787530
OpenAlexW4200410505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.